Melanoma Research Victoria

Patients with a stage III melanoma mutation treated with dabrafenib plus trametinib had longer restricted mean survival times compared with placebo, according to an analysis of a phase 3 trial presented at Maui Derm for Dermatologists.

Read the full story

Pathological response should be an early surrogate endpoint for clinical trials of neoadjuvant therapy for melanoma, according to results of a pooled analysis published in Nature Medicine.

Read the full story

Neoantigen long peptide vaccines (NeoVax) continued to show durable T-cell responses in patients with high-risk melanoma that persisted 4 years after initial vaccination, highlighting the ability of personalized cancer vaccines to provide long-term control against some cancers, according to results of a phase 1 study (NCT01970358) published in Nature Medicine.1,2

Read the full story

A personalized “cancer vaccine” may help keep a deadly form of skin cancer from growing for years, a small new study in humans suggests.

Read the full story